The effects of resveratrol supplement on some mediator genes of immunity and inflammation, inflammatory factors, oxidative stress and clinical outcomes in hospitalized acute ischemic stroke patients with enteral feeding in intensive care unit: A randomized triple-blind placebo-controlled trial

Start Date30 Dec 2024

Sponsor / Collaborator

Iran University of Medical Sciences & Health Services

CTRI/2024/12/077531

/ Not yet recruitingNot ApplicableIIT

Nutrigenomic Insights into Thalassemia: Resveratrols Influence on HIF-1a and Clock/BMAL1 Genes Expression, Oxidative Stress and bone mineral density (BMD) of North Indian Thalassemia Patients - NIL

Start Date26 Dec 2024

Sponsor / Collaborator

King George's Medical University

IRCT20240821062827N1

/ RecruitingNot ApplicableIIT

The effect of eight weeks of balance and rhythmic training and resveratrol supplement on daily activity ability index and SIRT1 in elderly women with Parkinson's disease

Start Date30 Nov 2024

Sponsor / Collaborator-

100 Clinical Results associated with Resveratrol

100 Translational Medicine associated with Resveratrol

100 Patents (Medical) associated with Resveratrol

17,412

Literatures (Medical) associated with Resveratrol

31 Dec 2025·Gut Microbes

Gut microbiota-derived 4-hydroxyphenylacetic acid from resveratrol supplementation prevents obesity through SIRT1 signaling activation

Article

Author: Ge, Zhiwen ; Zhao, Shuang ; Ma, Yue ; Zhao, Yuanyuan ; Zhao, Wenting ; Wang, Ruiqi ; Zhao, Xiaoyan ; Wang, Pan ; Wang, Dan

Resveratrol (RSV), a natural polyphenol, has been suggested to influence glucose and lipid metabolism. However, the underlying molecular mechanism of its action remains largely unknown due to its multiple biological targets and low bioavailability. In this study, we demonstrate that RSV supplementation ameliorates high-fat-diet (HFD)-induced gut microbiota dysbiosis, enhancing the abundance of anti-obesity bacterial strains such as Akkermansia, Bacteroides and Blautia. The critical role of gut microbiota in RSV-mediated anti-obesity effects was confirmed through antibiotic-induced microbiome depletion and fecal microbiota transplantation (FMT), which showed that RSV treatment effectively mitigates body weight, histopathological damage, glucose dysregulation and systematic inflammation associated with HFD. Metabolomics analysis revealed that RSV supplementation significantly increases the levels of the gut microbial flavonoid catabolite 4-hydroxyphenylacetic acid (4-HPA). Notably, 4-HPA was sufficient to reverse obesity and glucose intolerance in HFD-fed mice. Mechanistically,4-HPA treatment markedly regulates SIRT1 signaling pathways and induces the expression of beige fat and thermogenesis-specific markers in white adipose tissue (WAT). These beneficial effects of 4-HPA are partially abolished by EX527, a known SIRT1 inhibitor. Collectively, our findings indicate that RSV improve obesity through a gut microbiota-derived 4-HPA-SIRT1 axis, highlighting gut microbiota metabolites as a promising target for obesity prevention.

01 Nov 2025·Neural Regeneration Research

The compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one alleviates neuroinflammation and cognitive impairment in a mouse model of Alzheimer’s disease

Article

Author: Zheng, Huijuan ; Wang, Chengyan ; Chai, Ke ; Zha, Daijun ; Ye, Zu-Cheng ; Yao, Yuxing ; Yuan, Fanru ; Wu, Wei ; Liu, Xueyan ; Li, Chenlu ; Li, Xuejuan

JOURNAL/nrgr/04.03/01300535-202511000-00034/figure1/v/2024-12-20T164640Z/r/image-tiff Previous studies have shown that the compound (E)-2-(3,4-dihydroxystyryl)-3-hydroxy-4H-pyran-4-one (D30), a pyromeconic acid derivative, possesses antioxidant and anti-inflammatory properties, inhibits amyloid-β aggregation, and alleviates scopolamine-induced cognitive impairment, similar to the phase III clinical drug resveratrol. In this study, we established a mouse model of Alzheimer’s disease via intracerebroventricular injection of fibrillar amyloid-β to investigate the effect of D30 on fibrillar amyloid-β–induced neuropathology. Our results showed that D30 alleviated fibrillar amyloid-β–induced cognitive impairment, promoted fibrillar amyloid-β clearance from the hippocampus and cortex, suppressed oxidative stress, and inhibited activation of microglia and astrocytes. D30 also reversed the fibrillar amyloid-β–induced loss of dendritic spines and synaptic protein expression. Notably, we demonstrated that exogenous fibrillar amyloid-β introduced by intracerebroventricular injection greatly increased galectin-3 expression levels in the brain, and this increase was blocked by D30. Considering the role of D30 in clearing amyloid-β, inhibiting neuroinflammation, protecting synapses, and improving cognition, this study highlights the potential of galectin-3 as a promising treatment target for patients with Alzheimer’s disease.

01 Sep 2025·Neural regeneration research

Acquired sensorineural hearing loss, oxidative stress, and microRNAs.

Article

Author: Guo, Ru C ; Nunez, Desmond A

Hearing loss is the third leading cause of human disability. Age-related hearing loss, one type of acquired sensorineural hearing loss, is largely responsible for this escalating global health burden. Noise-induced, ototoxic, and idiopathic sudden sensorineural are other less common types of acquired hearing loss. The etiology of these conditions is complex and multi-factorial involving an interplay of genetic and environmental factors. Oxidative stress has recently been proposed as a likely linking cause in most types of acquired sensorineural hearing loss. Short non-coding RNA sequences known as microRNAs (miRNAs) have increasingly been shown to play a role in cellular hypoxia and oxidative stress responses including promoting an apoptotic response. Sensory hair cell death is a central histopathological finding in sensorineural hearing loss. As these cells do not regenerate in humans, it underlies the irreversibility of human age-related hearing loss. Ovid EMBASE, Ovid MEDLINE, Web of Science Core Collection, and ClinicalTrials.gov databases over the period August 1, 2018 to July 31, 2023 were searched with "hearing loss," "hypoxamiRs," "hypoxia," "microRNAs," "ischemia," and "oxidative stress" text words for English language primary study publications or registered clinical trials. Registered clinical trials known to the senior author were also assessed. A total of 222 studies were thus identified. After excluding duplicates, editorials, retractions, secondary research studies, and non-English language articles, 39 primary studies and clinical trials underwent full-text screening. This resulted in 11 animal, in vitro , and/or human subject journal articles and 8 registered clinical trial database entries which form the basis of this narrative review. MiRNAs miR-34a and miR-29b levels increase with age in mice. These miRNAs were demonstrated in human neuroblastoma and murine cochlear cell lines to target Sirtuin 1/peroxisome proliferator-activated receptor gamma coactivator-1-alpha (SIRT1/PGC-1α), SIRT1/p53, and SIRT1/hypoxia-inducible factor 1-alpha signaling pathways resulting in increased apoptosis. Furthermore, hypoxia and oxidative stress had a similar adverse apoptotic effect, which was inhibited by resveratrol and a myocardial inhibitor-associated transcript, a miR-29b competing endogenous mRNA. Gentamicin reduced miR-182-5p levels and increased cochlear oxidative stress and cell death in mice - an effect that was corrected by inner ear stem cell-derived exosomes. There is ongoing work seeking to determine if these findings can be effectively translated to humans.

News (Medical) associated with Resveratrol

13 Jan 2025

·www.globenewswire.com

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter, Florida, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today announced a strategic focus on targeting the NLRP3 inflammasome in all upcoming clinical trials. This shift aims to unlock new therapeutic potential for neurodegenerative diseases, longevity, and aging, positioning the Company at the forefront of innovation in neuroinflammation treatments. The NLRP3 inflammasome is a key inflammation driver linked to central nervous system (CNS) disorders, metabolic diseases, and aging-related conditions. JOTROL, Jupiter’s flagship product, overcomes resveratrol’s historical challenges of poor bioavailability and gastrointestinal side effects. With its ability to safely reach therapeutic levels in plasma and cross the blood-brain barrier, JOTROL represents a groundbreaking advance for targeting neuroinflammatory pathways like NLRP3. “By adding focus on NLRP3 evaluation, in addition to earlier established biomarkers, we expect to maximize JOTROL’s therapeutic potential in addressing unmet medical needs,” said Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “We believe JOTROL’s ability to inhibit NLRP3, based on multiple published resveratrol trials, makes it an ideal candidate for diseases such as Parkinson’s and Alzheimer’s, and it positions Jupiter to pursue additional collaborations, particularly in the rapidly growing obesity treatment market.” Advancing Parkinson’s and Alzheimer’s Research Preclinical studies at the University of Miami have demonstrated JOTROL’s ability to mitigate key biomarkers of Parkinson’s disease, making this a primary target for Jupiter’s future trials. The company also continues to refine its strategy for Alzheimer’s research, leveraging its prior Phase I pharmacokinetics study funded by the National Institute on Aging. The U.S. Senate’s recent passage of the "National Plan to End Parkinson’s Act" highlights the growing urgency for effective treatments, and Jupiter is aligning its clinical focus to capitalize on this momentum. With a $50 billion market for Alzheimer’s treatments and a $500 million opportunity in Parkinson’s, Jupiter is well-positioned to address these high-value areas. Market Expansion and Strategic Partnerships In addition to its CNS focus, Jupiter is evaluating opportunities in longevity and metabolic health. Emerging data suggests that JOTROL’s inhibition of NLRP3, when combined with GLP-1 treatments, could enhance weight loss outcomes, opening doors to potential collaborations in the obesity market—a multibillion-dollar industry. The Company is also pursuing expansion in the Asia-Pacific region, driven by strong interest from regional partners. Recent agreements to accelerate clinical development and regulatory approval underscore Jupiter’s commitment to global growth. Why JOTROL is Different JOTROL’s patented micellar delivery system allows resveratrol to reach effective concentrations in the bloodstream without causing gastrointestinal side effects—a longstanding barrier for resveratrol-based treatments. This innovative approach has been validated in peer-reviewed studies and forms the basis of Jupiter’s strategy to pursue regulatory approval across multiple indications. About Jupiter Neurosciences, Inc. Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. About JOTROL Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.\ Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. About NLRP3 The NLRP3 inflammasome is a critical component of the innate immune system that mediates caspase-1 activation and the secretion of proinflammatory cytokines IL-1β/IL-18 in response to microbial infection and cellular damage. However, the aberrant activation of the NLRP3 inflammasome has been linked with several inflammatory disorders, which include cryopyrin-associated periodic syndromes, Alzheimer’s disease, diabetes, and atherosclerosis. The NLRP3 inflammasome is activated by diverse stimuli, and multiple molecular and cellular events, including ionic flux, mitochondrial dysfunction, and the production of reactive oxygen species, and lysosomal damage have been shown to trigger its activation. Kelley N, Jeltema D, Duan Y, He Y. The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation. Int J Mol Sci. 2019 Jul 6;20(13):3328. doi: 10.3390/ijms20133328. PMID: 31284572; PMCID: PMC6651423. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contact: Dave GentryRedChip Companies, Inc.1-407-644-42561-800-RED-CHIP (733-2447)JUNS@redchip.com

Phase 1

04 Dec 2024

·www.globenewswire.com

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Jupiter, Florida, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL™, today announced the closing of its initial public offering of 2,750,000 shares of common stock at a price of $4.00 per share for gross proceeds of $11 million, before deducting underwriting discounts and other related expenses. The Company’s shares began trading on the Nasdaq Capital Market on December 3, 2024 under the symbol “JUNS.” The Company intends to use the net proceeds from the Offering to fund the Phase II clinical trial of its product candidate JOTROL™ in patients with Parkinson’s Disease, Strategic Service Agreements to accelerate business activities in South-East Asia, research and development activities regarding evaluation of new product opportunities, payment of the outstanding annual license fees due to Aquanova AG, the repayment of debt, working capital and other general corporate purposes. Dominari Securities LLC acted as the lead underwriter, with Revere Securities LLC acting as the co-manager for the offering. Anthony, Linder & Cacomanolis, PLLC acted as legal counsel to Jupiter Neurosciences and ArentFox Schiff LLP acted as legal counsel to the Underwriters in connection with the offering. The Company’s Registration Statement on Form S-1 (File No. 333- 260183) relating to the securities being offered was previously filed with, and subsequently declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2024. The offering was made by means of a prospectus, forming part of the Registration Statement. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus relating to the offering may be obtained, when available, from Dominari Securities LLC by email at info@dominarisecurities.com, by standard mail to Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor New York, NY 10022, or by telephone at (212) 393-4500; or from Revere Securities LLC by email at contact@reveresecurities.com, by standard mail to Revere Securities LLC, 560 Lexington Avenue, 16th Floor, New York, NY 10022, or by telephone at +1 (212) 688-2350. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the use of proceeds from the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contacts Investor RelationsAlison Silva, President & CBOa.silva@jupiterneurosciences.com

Phase 2

03 Dec 2024

·www.globenewswire.com

Jupiter Neurosciences, Inc. Announces Pricing of $11 million Initial Public Offering and Listing on Nasdaq

Jupiter, Florida, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (Nasdaq: JUNS) (the “Company” or “Jupiter Neurosciences”), a clinical stage pharmaceutical company advancing a pipeline targeting neuroinflammation with its unique resveratrol platform product, JOTROL™, today announced the pricing of its initial public offering (the “Offering”) of 2,750,000 shares of common stock at a price of $4.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on December 3, 2024 under the symbol “JUNS.” The Offering is expected to close on December 4, 2024, subject to the satisfaction of customary closing conditions. The Company expects to receive aggregate gross proceeds of $11 million from the Offering, before deducting underwriting discounts and other related expenses. The Company intends to use the net proceeds from the Offering to fund the Phase II clinical trial of its product candidate JOTROL™ in patients with Parkinson’s Disease, Strategic Service Agreements to accelerate business activities in South-East Asia, research and development activities regarding evaluation of new product opportunities, payment of the outstanding annual license fees due to Aquanova AG, the repayment of debt, working capital and other general corporate purposes. The Offering is conducted on a firm commitment basis. Dominari Securities LLC is acting as the lead underwriter, with Revere Securities LLC acting as the co-manager (collectively, the “Underwriters”) for the Offering. Anthony, Linder & Cacomanolis, PLLC is acting as legal counsel to Jupiter Neurosciences and ArentFox Schiff LLP is acting as legal counsel to the Underwriters in connection with the Offering. The Company’s Registration Statement on Form S-1 (File No. 333- 260183) relating to the securities being offered was previously filed with, and subsequently declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on November 8, 2024. The Offering is being made only by means of a prospectus. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus relating to the Offering may be obtained, when available, from Dominari Securities LLC by email at info@dominarisecurities.com, by standard mail to Dominari Securities LLC, 725 Fifth Avenue, 23rd Floor New York, NY 10022, or by telephone at (212) 393-4500; or from Revere Securities LLC by email at contact@reveresecurities.com, by standard mail to Revere Securities LLC, 560 Lexington Avenue, 16th Floor, New York, NY 10022, or by telephone at +1 (212) 688-2350. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Jupiter Neurosciences, Inc. Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on treating neuroinflammation, with a current focus on CNS disorders and rare diseases. The Company’s platform product, JOTROL™, is an enhanced orally administered resveratrol formulation designed and intended to deliver therapeutically relevant, safe levels of resveratrol. The Company’s pipeline is focused broadly on CNS disorder and includes indications such as Alzheimer’s Disease, Parkinson’s Disease, Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com. FORWARD-LOOKING STATEMENTS Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the timing of the trading of its common stock or the closing of the Offering. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Contacts Investor RelationsAlison Silva, President & CBOa.silva@jupiterneurosciences.com

Phase 2

100 Deals associated with Resveratrol

External Link

KEGG	Wiki	ATC	Drug Bank
-	Resveratrol	-	DB02709

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Multiple Myeloma	Phase 2	GB	Sirtris Pharmaceuticals, Inc.	30 Mar 2009
Multiple Myeloma	Phase 2	DK	Sirtris Pharmaceuticals, Inc.	30 Mar 2009
Dementia	Phase 2	-	Evolva Holding SA	-
Alzheimer Disease	Phase 1	US	Protheragen, Inc.	-
Infertility	Discovery	ES	IVI Madrid SL	13 Mar 2018
Ovarian Hyperstimulation Syndrome	Discovery	ES	IVI Madrid SL	13 Mar 2018
Colorectal Cancer	Discovery	GB	GSK Plc	19 Aug 2008
Liver metastases	Discovery	GB	GSK Plc	19 Aug 2008
Parkinson Disease	Discovery	PT	BIAL-Portela & Cia SA	04 May 2004

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03743636 (NICE, CTgov)	Phase 3	Peripheral Arterial Disease	90	Nicotinamide riboside+Resveratrol (Nicotinamide Riboside + Resveratrol)	bovwakfwdx(dzbvpuosvq) = cieijyazfh vdexzumdje (lloqadpnuq, thsiwjjijo - kqijykglgl) View more	-	14 Jan 2025
				Placebo+Nicotinamide riboside (Nicotinamide Riboside + Placebo)	bovwakfwdx(dzbvpuosvq) = bshrzioocp vdexzumdje (lloqadpnuq, rkaflrhxjj - qjjjgxaezq) View more
ESMO_ASIA2024	Not Applicable	Breast Cancer Nucleolin (Ncl)	-	Resveratrol-loaded porous silicon nanocarriers	zlgbyzqqkc(ctnzmlfxom) = xusruufkzl quxetmtdxo (quoixwatap ) View more	-	07 Dec 2024
				Free Resveratrol	zlgbyzqqkc(ctnzmlfxom) = obfmmcbrmn quxetmtdxo (quoixwatap ) View more
Biospace Manual	Phase 2	Peripheral Arterial Disease	90	Nicotinamide Riboside	(emkrkmsoin) = iuudvdcbmb schcytfvgm (wbsqczqnpa )	Positive	24 Jun 2024
				Nicotinamide Riboside combination with resveratrol	-
ESC2023	Not Applicable	Marfan Syndrome	57	Resveratrol	vrxknignuo(omtiambyno) = zedlcbodua vjljscyxax (eugqlzoatm )	-	26 Aug 2023
NCT02123121 (REVIVE, CTgov)	Phase 2	Mitochondrial Diseases	60	Vegetable cellulose (Vegetable Cellulose)	igaqkdnwej(hsfwtcokyw) = qrppmzpvfa ifacxglcee (kklhxkvvnk, reokkumypf - beaaybeznb) View more	-	27 Jul 2023
				All groups+Resveratrol 1000 mg/day (Resveratrol 1000 mg/Day)	igaqkdnwej(hsfwtcokyw) = knfwvyzdmy ifacxglcee (kklhxkvvnk, lpscbzarzu - ebbhekuxkh) View more
EASL_LCS2023	Not Applicable	-	-	Mangiferin	igxwqrapew(rhvsotqehv) = remarkable enhancement in CD8+ cytotoxic effect vejqwpbvcr (ghudxujvmy ) View more	-	20 Apr 2023
				Resveratrol
NCT04400890 (CTgov)	Phase 2	COVID-19	105	Vitamin D3+Resveratrol (Resveratrol With Vitamin D3)	ucuvzikynr(egrioqitjg) = kcntajuabp elbftlspmy (dykpthwulx, cjjfafqjyo - zcavizlfeo) View more	-	24 Feb 2023
				Vitamin D3 (Placebo With Vitamin D3)	ucuvzikynr(egrioqitjg) = fssjtqdoty elbftlspmy (dykpthwulx, emmavxfrlv - jwotlszryz) View more
NCT03253913 (RESULT, CTgov)	Phase 2	Lymphangioleiomyomatosis	25	Sirolimus+Resveratrol	tnmcaywysy(mxihjjkmtw) = ohryohgsev eakrrdrosy (olbmphghtl, rpihlafcnv - fnmxaoxsjd) View more	-	01 Feb 2023
NCT04867252 (Pubmed \| Endocrine)	Phase 2	Polycystic Ovary Syndrome	88	Metformin and Pioglitazone	mxuerrgfgo(vwscvqfvsr) = mfgorzgaqu zxqqdljtxw (ixvutjaefx )	Positive	28 Sep 2022
				Resveratrol and Myoinositol	mxuerrgfgo(vwscvqfvsr) = mhkioaddcu zxqqdljtxw (ixvutjaefx )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Resveratrol

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation